A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
研究单位：[1]Hoffmann-La Roche[2]Peking Union Medical College Hospital,Beijing City,China,100032[3]Peking University Third Hospital,Beijing,China,100191[4]Beijing Hospital of Ministry of Health[5]Hematology,Beijing,China,100730[6]Beijing Tongren Hospital, Capital Medical University,Beijing,China,100730[7]The First Bethune Hospital of Jilin University,Changchun,China[8]Ruijin Hospital Shanghai Jiaotong University School of Medicine[9]hemotology,Shanghai City,China,200025[10]Tongji Hospital of Tongji University,Shanghai,China,200065[11]The Fourth Hospital of Hebei Medical University[12]Hematology department,Shijiazhuang,China[13]Shanxi Province Cancer Hospital,Taiyuan City,China,030013[14]Tianjin Medical University General Hospital,Tianjin,China,300052[15]Tianjin Cancer Hospital,Tianjin,China,300060[16]Xinjiang Medical University Cancer Hospital,Urumqi City,China,830011[17]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan City,China,430023[18]Wuxi People''s Hospital,Wuxi,China,214023[19]First Affiliated Hospital of Medical College of Xi''an Jiaotong University,Xi''an,China,710061[20]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,China[21]Henan Cancer Hospital[22]Oncology,Zhengzhou,China
研究目的：
The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
